New Weight Loss Drug Needs Just 12 Shots a Year

Managing obesity could soon become much easier for millions of people worldwide.

Pfizer announced promising mid-stage trial results for berobenatide, a new weight loss drug that requires just one injection per month instead of weekly shots. For patients treating obesity as a chronic condition, that means 12 injections annually instead of 52.

The drug works like current blockbuster treatments such as Ozempic and Wegovy by mimicking GLP-1, a gut hormone that regulates blood sugar, slows digestion and reduces appetite. But Pfizer engineered it to remain in the bloodstream much longer, keeping those benefits active for an entire month.

In the VESPER-3 clinical study, patients without diabetes lost up to 12.3% of their body weight. Even more encouraging, people who switched from weekly to monthly dosing continued losing weight rather than hitting a plateau.

Dr. Anoop Misra, Chairman at Fortis CDOC Hospital for Diabetes and Allied Sciences, says the convenience factor matters more than comparing weight loss percentages. "Less frequent dosing has the potential to improve treatment persistence, which is a major determinant of long-term success in obesity management," he explains.

The innovation could prove especially valuable in India, where sticking with long-term treatments remains a major challenge. Monthly injections may reduce treatment fatigue and help patients stay committed to their health goals over time.

Patients would start with weekly doses before transitioning to the once-monthly schedule. While existing drugs like Wegovy and Zepbound have shown slightly higher weight loss in some studies, berobenatide's main advantage lies in its dosing schedule rather than raw efficacy.

The drug is now moving into Phase 3 trials, with 10 late-stage clinical studies planned or underway. Regulators will examine long-term safety, side effects, cardiovascular benefits and whether the extended drug exposure causes any unique concerns.

The Bright Side

A monthly injection could transform how doctors and patients view obesity treatment. Just as people take monthly medications for conditions like diabetes or hypertension, this approach reinforces that obesity is a chronic disease requiring ongoing management, not a temporary problem.

The convenience factor alone could keep more people on treatment long enough to see lasting results. Treatment fatigue is real, and reducing injection frequency from every week to every month removes a significant barrier to success.

If approved around 2028 or 2029 as expected, berobenatide could make effective obesity treatment accessible to more people who might have avoided weekly injections.

One shot per month could be the key to helping millions stay healthy for the long haul.